NASDAQ:ACXP Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free ACXP Stock Alerts $1.94 -0.03 (-1.52%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$1.90▼$2.0350-Day Range$1.64▼$3.0052-Week Range$1.17▼$8.82Volume20,197 shsAverage Volume145,221 shsMarket Capitalization$30.57 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Acurx Pharmaceuticals alerts: Email Address Acurx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside518.6% Upside$12.00 Price TargetShort InterestBearish4.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.97) to ($2.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.01 out of 5 starsMedical Sector771st out of 905 stocksPharmaceutical Preparations Industry368th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Acurx Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.80% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently increased by 71.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACXP. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Acurx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest22 people have searched for ACXP on MarketBeat in the last 30 days. This is an increase of 633% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders35.30% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.53% of the stock of Acurx Pharmaceuticals is held by institutions.Read more about Acurx Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acurx Pharmaceuticals are expected to decrease in the coming year, from ($0.97) to ($2.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 5.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Acurx Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> About Acurx Pharmaceuticals Stock (NASDAQ:ACXP)Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Read More ACXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACXP Stock News HeadlinesMay 8, 2024 | americanbankingnews.comAcurx Pharmaceuticals (ACXP) Scheduled to Post Quarterly Earnings on WednesdayMay 2, 2024 | finance.yahoo.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceMay 8, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 2, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceApril 25, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific ConferenceApril 23, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business UpdateApril 17, 2024 | nasdaq.comAcurx Pharmaceuticals Rings the Closing BellMarch 20, 2024 | seekingalpha.comAcurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call TranscriptMay 8, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 19, 2024 | markets.businessinsider.comAcurx Pharmaceuticals: Strong Buy on Ibezapolstat’s Promising Phase 3 Trials and Strategic PartnershipsMarch 19, 2024 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | finance.yahoo.comQ4 2023 Acurx Pharmaceuticals Inc Earnings CallMarch 18, 2024 | investorplace.comACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023March 18, 2024 | finance.yahoo.comWe Think Acurx Pharmaceuticals (NASDAQ:ACXP) Needs To Drive Business Growth CarefullyMarch 18, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 4, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business UpdateFebruary 27, 2024 | finance.yahoo.comAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentFebruary 27, 2024 | prnewswire.comAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentFebruary 17, 2024 | finance.yahoo.comACXP Mar 2024 4.000 callFebruary 16, 2024 | finance.yahoo.comACXP Mar 2024 5.000 putFebruary 2, 2024 | finance.yahoo.comNew to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PTFebruary 1, 2024 | finance.yahoo.comNew to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PTJanuary 26, 2024 | finance.yahoo.comNew to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PTJanuary 23, 2024 | finance.yahoo.comAcurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024January 17, 2024 | msn.comAcurx stock plunges 26% amid Phase 2 data release for C. diff drugJanuary 17, 2024 | msn.comELAB, KIND and RLX among pre-market losersJanuary 17, 2024 | markets.businessinsider.comAcurx Announces Positive Microbiology And Microbiome Data For Ibezapolstat From Phase 2b TrialSee More Headlines Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2024Today5/08/2024Next Earnings (Confirmed)5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACXP CUSIPN/A CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+509.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-289.69% Return on Assets-185.19% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book5.79Miscellaneous Outstanding Shares15,760,000Free Float10,195,000Market Cap$31.05 million OptionableOptionable Beta-1.79 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Robert J. DeLuccia (Age 78)Co-Founder & Executive Chairman Comp: $701.54kMr. David P. Luci CPA (Age 57)Esq., J.D., Co-Founder, President, CEO & Director Comp: $668.98kMr. Robert G. Shawah CPA (Age 57)CPA, Co-Founder & CFO Comp: $470.29kKey CompetitorsDaré BioscienceNASDAQ:DAREViracta TherapeuticsNASDAQ:VIRXTheratechnologiesNASDAQ:THTXNRx PharmaceuticalsNASDAQ:NRXPEnlivex TherapeuticsNASDAQ:ENLVView All CompetitorsInstitutional OwnershipProspect Financial Services LLCBought 17,700 shares on 4/23/2024Ownership: 1.732%NBC Securities Inc.Bought 14,000 shares on 4/5/2024Ownership: 0.089%Prospect Financial Services LLCBought 255,150 shares on 2/20/2024Ownership: 1.853%View All Institutional Transactions ACXP Stock Analysis - Frequently Asked Questions Should I buy or sell Acurx Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACXP shares. View ACXP analyst ratings or view top-rated stocks. What is Acurx Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued 12-month price targets for Acurx Pharmaceuticals' stock. Their ACXP share price targets range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 518.6% from the stock's current price. View analysts price targets for ACXP or view top-rated stocks among Wall Street analysts. How have ACXP shares performed in 2024? Acurx Pharmaceuticals' stock was trading at $3.83 at the start of the year. Since then, ACXP stock has decreased by 49.3% and is now trading at $1.94. View the best growth stocks for 2024 here. Are investors shorting Acurx Pharmaceuticals? Acurx Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 579,100 shares, an increase of 71.6% from the March 31st total of 337,400 shares. Based on an average daily volume of 103,300 shares, the days-to-cover ratio is currently 5.6 days. Approximately 4.8% of the company's stock are short sold. View Acurx Pharmaceuticals' Short Interest. When is Acurx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our ACXP earnings forecast. How can I listen to Acurx Pharmaceuticals' earnings call? Acurx Pharmaceuticals will be holding an earnings conference call on Wednesday, May 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Acurx Pharmaceuticals' earnings last quarter? Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) released its earnings results on Friday, March, 15th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.12. When did Acurx Pharmaceuticals IPO? Acurx Pharmaceuticals (ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities acted as the underwriters for the IPO. Who are Acurx Pharmaceuticals' major shareholders? Acurx Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Prospect Financial Services LLC (1.73%), NBC Securities Inc. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia. View institutional ownership trends. How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACXP) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
